in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Sanofi Pasteur, Klöckner Pentaplast and Geron.
The biomanufacturing industry needs to adopt an integrated approach to upstream and downstream processing to boost efficiency and productivity according to EMD Millipore.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including a new head of vaccines at Sanofi and another exec moving from Pfizer to AstraZeneca.
CardioGenics predicts yield boosting “biologics beads” will change the antibody extraction landscape after signing distribution deal with Merck Chimie.
Cellexus has expanded its disposable bioreactor offering with a unit designed to give biomanufacturers greater flexibility in their choice of cell lines.
Germany’s Merck KGaA has completed its $7bn (€b5.2n) acquisition of Millipore, unveiling plans to target “high-growth, high-margin” bio-research and bio-production markets.
Archimica has entered into an exclusive distribution agreement with a Merck KGaA subsidiary to provide building blocks and special reagents for organic synthesis.
Millipore has expanded its microbial detection offering with Milliflex Quantum which, it says, enables manufacturers to respond to contamination issues earlier in the drug and vaccine production process.
German pharmaceutical firm Merck KGaA says proposed Millipore acquisition will transform its chemicals unit and give it a more balanced business profile.
Merck KGaA has begun work on a new inorganic salts plant in Darmstadt, Germany, citing growing demand as the main motivation for the €30m ($42m) investment.
Merck Serono, the small molecules development division of Germany’s Merck KGaA, will use Aegis Analytical’s Discoverant data management and analytics platform at its manufacturing facility in Vevey Switzerland.
Sanofi-Aventis had a €5bn ($6.6bn) bid for Solvay’s pharma business rejected, according to media reports, but several other companies are believed to be interested in the Belgian firm.
Merck Serono has stumped up $13m (€9m) to add manufacturing rights to its Stimuvax licensing deal with Oncothyreon and buy up any remaining inventory of the candidate lung cancer vaccine.
Taiwan’s efforts to position itself as a major biotechnology hub received a further boost today with the opening of Merck KGaA’s dedicated technology training centre in Xizhi City, Taipei County.
In a shock announcement at its third quarter financial results,
Merck KGaA has said it will stop its diabetes research and partner
out any current programmes.
After months of speculation and bartering following Merck KGaA's
decision to put its generics arm up for sale, the winning bid has
finally been announced, with US firm Mylan Laboratories emerging
victorious beating off the competition...
VWR's parent company has signed a definitive agreement to sell the
world's second largest laboratory supplier after its recent period
of significant growth and profitability.
Merck KGaA last week confirmed that it is considering selling off
its generics division, prompting mass speculation over potential
buyers within the industry.
German drug manufacturer, Merck has acquired the Swiss biotech
company Serono in a deal worth SFr16.6bn (€10.4bn) that has taken
the industry by surprise and could signal the start of considerable
consolidation for big pharma.
Germany's Merck has announced its biggest investment in
pharmaceuticals in its 338-year-old history, as its top-selling
oncology drug Erbitux (cetuximab) has driven the company to
allocate €190m for the construction of its first...
The break up of global fine and specialty chemicals company Avecia
continued as Fujifilm said it would take over Avecia Inkjet
formally next month. The €220 million fee to acquire the company's
Inkjet and Electrophotography...
Merck KGaA announced its intention to relocate its pharmaceutical
research operations in Scotland to its larger biotech research
facility in the United States, withdrawing its DeImmunisation
technology service at the same time.
Merck KGaA is planning to sell its electronic chemicals business to
BASF for €270 million, freeing it up to focus on its
pharmaceutical, chemical and liquid crystal businesses.
Busy times for personnel in the pharmaceutical technology sector,
with a series of new appointments at the senior level in
ingredients, separation and drug delivery companies.
German chemical and pharmaceutical company Merck KGaA has sold off
a manufacturing facility in France in a move aimed at consolidating
its global production infrastructure.
Belgian group UCB, fresh from making an offer for UK biotech
company Celltech, has announced plans to sell off its chemicals
unit and become a pharmaceuticals pure play, reports Phil
Taylor.
Around 80 workers from Merck KGaA's French site at Lacassagne in
Lyon have taken part in a protest at the company's headquarters in
Darmstadt, Germany, against the planned closure of the unit.
BASF IT Services, one of the first units of the German chemical
major to be spun out into a separate unit, has signed an agreement
with Merck KGaA that confirms its ability to win major contracts
from companies other than its parent.
The restructuring activity that has features this year in the
European pharmachem industry continued yesterday with the news that
Germany's Merck KGaA had sold off BioMer, a joint venture focusing
on orthopaedic products.
Merck KGaA drops plans to build a €300m biomanufacturing plant in
Jena, Germany, on the grounds that late-stage product failures have
left plenty of free capacity in the contract sector. The company's
move suggests that the often-repeated...
Germany's Merck KGaA has almost completed the construction of a
€200 million plant that will provide a significant increase in the
company's organic synthesis business.
Merck KGaA buys ProteoPlex in a move designed to shore up its
position in the emerging microarray market, estimated to reach $2
billion (€1.76bn) in 2008.
Germany-based drugmaker Merck KGaA has launched a major
restructuring of its R&D activities after shelving two of its
early-stage diabetes product candidates, EML 16336 and IDD 676.
